Russ Conroy

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Results from the CARTITUDE-2 trial support cilta-cel in patients with multiple myeloma, which addresses the unmet needs of these patients, an expert presented.

All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.

Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Stereotactic ablative body radiotherapy in primary renal cell cancer may be a treatment approach with an acceptable adverse effect profile and with minimal impact on renal function.

The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Simple hysterectomy was shown to reduce the incidence of urinary incontinence vs radical hysterectomy for low-risk cervical cancer.

Cancer teams, including oncology nurses, can make conscious choices to potentially alleviate the disparities that persist in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Although frontline treatment with lenvatinib plus pembrolizumab improved ORR and PFS, it did not improve OS when compared with placebo in patients with head and neck squamous cell carcinoma.

It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.

Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.

All prespecified patient subgroups with metastatic urothelial cancer showed a clinical benefit with sacituzumab govitecan plus pembrolizumab in cohort 3 of the phase 2 TROPHY-U-01 trial.

The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.

Cabozantinib plus atezolizumab may be a new treatment option for patients with metastatic castration-resistant prostate cancer whose disease progressed on novel hormonal therapy.

Fruquintinib showed potential in providing an improved quality of life and survival benefit in patients with previously treated metastatic colorectal cancer.

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

Patients treated with mRNA-4157 plus pembrolizumab experienced an approximately 44% reduction in the risk of death or recurrence compared to those receiving pembrolizumab alone.

Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.

Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.

Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.